Transanal endoluminal surgery (TES) shows significant advantages over endoscopic submucosal dissection (ESD) for T1 rectal cancer.

• 1-year mortality: 2.3% for TES vs. 10.1% for ESD; 10-year mortality: 11.6% vs. 27.1%.
• Hospital readmissions at 1 month: 3.4% for TES vs. 19.6% for ESD.
• Fewer complications with TES, including reduced procedural pain and thromboembolic events.

Choose TES for lower mortality and complications, tailoring decisions to patient-specific factors.